[ADVERT]
Share Name Share Symbol Market Type Share ISIN Share Description
Nuformix Plc LSE:NFX London Ordinary Share GB00BYW79Y38 ORD 0.1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.25 21.28% 1.425 1.35 1.50 1.55 1.175 1.18 20,923,218 15:40:45
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Nonequity Investment Instruments 0.2 -1.4 -0.2 - 8

Nuformix Share Discussion Threads

Showing 7701 to 7722 of 7825 messages
Chat Pages: 313  312  311  310  309  308  307  306  305  304  303  302  Older
DateSubjectAuthorDiscuss
13/9/2021
12:17
Underwhelming is an understatement!I'm aghast at how it's even possible to fail to add any noticeable shareholder value when a plc signs an exclusive global licensing deal for oncology treatments. We were supposed to be worth between 1.7p and 3.4p before any deals were struck! Here we are at 1.45p after 20m trades.Oxilio now have a pipeline which includes OXL001 and a new indication: OXL002 (check out the website) I'm almost dreading the thought that the new product might be linked to another one of ours given todays lack-lustre response by the market.You'd have thought the directors would be filling their boots with shares if that is the end of the closed period.
for fx sake
13/9/2021
09:07
Why no mention of the up front payment value , also having payments based on net profit means very little , sounds like rubbish deal , no wonder it has not impressed the market .
jotoha2
13/9/2021
07:43
Great news
whocares765
13/9/2021
07:39
Christmas till will be substantially higher. Cash generative now.
tomtum1
13/9/2021
07:28
Forget 2p. The important tipping point (where we start heading north) will be when we're cash generative. That time is now.
david gruen
13/9/2021
07:26
Under the terms of the licensing agreement, Oxilio has obtained an exclusive licence to research, develop and commercialise NXP001 globally for oncology indications. Nuformix is eligible to receive an undisclosed upfront payment, development milestone payments and a royalty on net sales, capped at GBP2 million per annum.
tomboyb
13/9/2021
07:26
Looks interesting -
tomboyb
13/9/2021
07:24
RNS Number : 4839L Nuformix PLC 13 September 2021 13 September 2021 Nuformix plc ("Nuformix" or the "the Company") Worldwide licensing agreement with Oxilio for NXP001 Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, is pleased to announce that it has signed an exclusive global licensing agreement with Oxilio Ltd ("Oxilio"), a privately held pharmaceutical development company, for NXP001 (a proprietary new form of aprepitant) for oncology indications. Under the terms of the licensing agreement, Oxilio has obtained an exclusive licence to research, develop and commercialise NXP001 globally for oncology indications. Nuformix is eligible to receive an undisclosed upfront payment, development milestone payments and a royalty on net sales, capped at GBP2 million per annum. -- On 23 September 2020, Nuformix granted an exclusive option to Oxilio to license NXP001 globally for oncology indications. This triggered an undisclosed upfront payment. -- On 22 March 2021, Oxilio exercised its option to acquire a licence for NXP001. Oxilio and Nuformix then began working together to finalise an exclusive global licensing agreement for NXP001. Dr Anne Brindley, CEO of Nuformix, said: "We are delighted to complete the licensing agreement with Oxilio - achieving this exclusive global licensing deal for NXP001 in oncology is a major step forward as it validates the Nuformix technology and intellectual property, and also endorses our strategy of repurposing drugs and licensing at an early stage. Nuformix will now concentrate on developing its two lead assets NXP002 and NXP004." Dr Simon Yaxley, Co-Founder and Director of Oxilio said: "We are pleased to expand our clinical development pipeline with the licensing of NXP001, which is highly complementary to our strategy of identifying, repurposing and commercialising existing drugs to address unmet needs in cancer therapy . NXP001 , a novel form of aprepitant with improved properties, and its Phase 1 study demonstrates the potential for improved bioavailability without needing a complex formulation. Our hope is for the consolidated efforts under the agreement to enable Oxilio to accelerate the development of NXP001 and bring new treatment options to a broad range of cancer patients."
david gruen
13/9/2021
07:16
I don't read twitter, just the RNS is all I need. Let's hope for upward momentum going forward now
hollywood6
13/9/2021
07:13
Get in lovely NFX dealNow over 2p pleaseHTTPS://www.twitter.com/DVH_Phoenix/status/1437298053648637953
whocares765
13/9/2021
07:08
Great news
hollywood6
09/9/2021
22:16
It’s not nfx but it’s a preclinical study that shows inhalation is better than intravenously injections in the vein In preclinical studies, PRS-220, Pieris Pharmaceuticals’ experimental inhaled therapy for idiopathic pulmonary fibrosis (IPF), showed stronger lung tissue penetration and anti-scarring effects than pamrevlumab — an into-the-vein, mechanistically similar IPF therapy currently being tested in a Phase 3 clinical trial. These promising findings, which support Pieris’ plans to launch a Phase 1 trial of PRS-220 next year, were presented in a poster titled, “Development of PRS-220, a potential best-in-class, inhaled CTGF/CCN2 inhibitor for the treatment of IPF,” at the European Respiratory Society International Congress 2021, held virtually Sept. 5–8. “PRS-220 exemplifies our respiratory strategy of advancing programs addressing clinically-validated targets where a local approach may provide significant benefit to patients,” Shane Olwill, PhD, Pieris’ chief development officer, said in a press release. Connective tissue growth factor (CTGF) is a protein found at higher-than-normal levels in the lung tissue of people with IPF. It contributes to the progressive and excessive tissue scarring (fibrosis) characteristic of the disease. As such, therapeutic approaches suppressing CTGF are thought to have the potential to prevent the activation of downstream pro-inflammatory and pro-fibrotic factors, thereby slowing or halting IPF progression. In agreement, pamrevlumab — FibroGen’s experimental anti-CTGF antibody that is delivered directly into the bloodstream — was shown to safely and effectively slow lung function decline in IPF patients in a Phase 2 trial (NCT01890265). Https://pulmonaryfibrosisnews.com/2021/09/08/inhaled-prs-220-superior-into-the-vein-pamrevlumab-idiopathic-pulmonary-fibrosis-ipf-preclinical-data/
spurs90
06/9/2021
16:17
Preclinical studies show potential for single agent and combination use. Data from an in vitro IPF model has shown anti-fibrotic/anti-inflammatory activity of NXP002 alone and in combination with two approved IPF drugs. These studies suggest the addition of NXP002 may achieve the same or better activity at lower doses of the approved drugs, which may offer advantages as both have challenging side effects. Additional preclinical studies are planned as Nuformix builds out a more robust data package. Results due Q4 2021 Progress on NXP004. Research is also underway on developing new forms of an undisclosed marketed oncology drug (with sales c.$1.5bn in 2020). Results Due Q4 2021. A patent filed in 2020 may be granted in 2022. Licensing deal under negotiation with Oxilio. A licensing deal is being finalised with Oxilio, a private UK company, for NXP001, a novel formulation of aprepitant intended for cancer treatment. Licensing agreement could be announced anytime soon. Indicative value NXP002 . We believe a licensing deal or partnership for NXP002 as a Phase 1-ready asset for IPF could have a $360-450m headline value, although the upfront would be likely to be in the $10-20m range. Although, the economics of such deals are difficult to predict, the future NPV of this asset alone could be +£50m. Fully funded Cash to 2023. Nuformix results show net cash of £1.6m, giving a runway into late CY2022
spurs90
06/9/2021
12:56
susiebe 19 Feb '21 - 15:29 - 79181 of 79184 0 1 0 Sentiment Riles just give up. Have never seen such an embarrassing poster as you
bobby semen
06/9/2021
12:35
Some melt diwn on the rise commencing 😂😂😂😂
sentiment riles
06/9/2021
12:31
susiebe 19 Feb '21 - 15:29 - 79181 of 79184 0 1 0 Sentiment Riles just give up. Have never seen such an embarrassing poster as you
bobby semen
06/9/2021
12:30
The ides of march 23 May '21 - 09:06 - 29940 of 29946 0 1 0 Sentiment Riles - during his junior school days ,he was always last to be picked on the play ground. The kid no one wanted on their team. Whilst that’s not very nice , it partially explains how SR has become the person he is today . Unable to form friendships, this guy is un balanced, (even the bears refuse to take him in ) and as such this reflects into his investing strategy ... Needless to say his record is shockingly poor . What’s worse though is he is a loser in life.
bobby semen
06/9/2021
12:29
Opti is falling Nfx rising I don’t need to check I just wait for the scum troll posts 😂
sentiment riles
06/9/2021
12:28
facts are facts folks universally laughed at is riles The ides of march 23 May '21 - 09:06 - 29940 of 29946 0 1 0 Sentiment Riles - during his junior school days ,he was always last to be picked on the play ground. The kid no one wanted on their team. Whilst that’s not very nice , it partially explains how SR has become the person he is today . Unable to form friendships, this guy is un balanced, (even the bears refuse to take him in ) and as such this reflects into his investing strategy ... Needless to say his record is shockingly poor . What’s worse though is he is a loser in life.
bobby semen
06/9/2021
12:19
Looking nice move
sentiment riles
05/9/2021
20:48
Fair enough. Didn't recognise the different name
for fx sake
05/9/2021
20:02
Listed as 6.65% High Value Manufacturing Catapult Https://www.uk-cpi.com/about/partnerships/high-value-manufacturing-catapult CPI is the process manufacturing partner in the government’s elite High Value Manufacturing Catapult. This awards CPI direct involvement in UK and EU science and innovation strategy alongside sustained investment to ensure our staff and facilities are at the cutting edge of product and process development.
spurs90
Chat Pages: 313  312  311  310  309  308  307  306  305  304  303  302  Older
ADVFN Advertorial
Your Recent History
LSE
NFX
Nuformix
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20211022 04:55:17